Did Everolimus Break the Rules?

A phase II study with everolimus (mTORC1 inhibitor) among advanced solid tumors patients with or alterations was recently published. Although efficacy was limited, the study provided the future groundwork to advance the targeted therapy approach. .

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-07, Vol.27 (14), p.3807-3808
Hauptverfasser:	Kato, Shumei, Cohen, Ezra E W
Format:	Artikel
Sprache:	eng
Schlagworte:	Everolimus Humans Mechanistic Target of Rapamycin Complex 1 Tuberous Sclerosis Complex 2 Protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A phase II study with everolimus (mTORC1 inhibitor) among advanced solid tumors patients with or alterations was recently published. Although efficacy was limited, the study provided the future groundwork to advance the targeted therapy approach. .
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-21-1508